340B Discounts Withheld Through Contract Pharmacy Restrictions Equal 10% of Overall Program Sales

Data from the US Health and Human Services Department quantify the financial impact of manufacturer 340B “integrity” initiatives on hospitals and other providers over the past several months.

Contract Pharmacies Account For Major Portion Of 340B Sales • Source: Alamy

Actions taken by several manufacturers to restrict 340B discounts on outpatient drugs provided to contract pharmacies over the past year or so has led to a significant reduction in savings at a rate of at least $3.2bn annually, according to data compiled by the Health and Human Services Department.

That would represent nearly 10% of overall sales in the 340B drug discount program, which topped $38bn in 2020. The...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access